For many Americans on GLP-1 medications, optimism about living longer is arriving faster than the financial plan to pay for it.
A survey published by the Nationwide Retirement Institute found that 51% of current GLP-1 users worry they may have to choose between paying for their medication and saving enough for retirement. Nearly a quarter say maintaining access to their medication already takes priority over increasing retirement savings. The research, conducted by The Harris Poll among 1,933 US adults between July 20 and August 4, included oversamples of 509 current and 364 former GLP-1 users.
What makes those numbers more than a snapshot of financial anxiety is what is already happening on the ground. More than half of current users, or 54%, have changed their financial behaviors to afford the medication, including 17% who have taken on debt, 14% who have withdrawn money from savings or retirement accounts, and 14% who have reduced retirement contributions. Users whose coverage does not fully cover the cost pay an average of $203 out of pocket each month, according to the survey.
The study also captures a subtler problem. Nearly nine in 10 current users say taking a GLP-1 makes them more optimistic about their long-term health. That optimism appears to be reshaping how they think about future costs. Fifty-nine percent say the expected health benefits make them feel less pressure to increase retirement savings, while 57% say those same benefits make them less concerned about needing additional health or long-term care insurance down the road.
The risk embedded in that outlook is that a healthier life is also, typically, a longer one. Fifty-six percent of current users acknowledge they may need more money for healthcare if they live longer, and 49% say the prospect of a longer life makes them less confident in their current retirement plan. The medication that is reducing their sense of financial urgency may ultimately extend the retirement they are less prepared to fund.
The financial strain users are already experiencing sits against a backdrop of increasingly uncertain employer coverage. According to the International Foundation of Employee Benefit Plans' July 2026 survey of employers, 60% now cover GLP-1s for diabetes only, up from 49% in 2023. The share covering them for both diabetes and weight loss has held at 36%.
The Business Group on Health, which surveyed 127 large employers, found that about 14% have already dropped or plan to drop obesity drug coverage in 2027.
The Nationwide survey captures what happens when coverage narrows. Among former GLP-1 users, 28% stopped because their health insurance reduced or eliminated coverage, and 27% stopped because of changes to their personal finances. Coverage loss and cost, in other words, are nearly equal drivers of discontinuation, and both carry their own health and financial risks for people who have come to rely on the medication.
Against that, the Centers for Medicare and Medicaid Services (CMS) launched the Medicare GLP-1 Bridge program on July 1, giving eligible Part D beneficiaries access to certain GLP-1 medications for $50 a month through December 31, 2027, a temporary measure while longer-term policy decisions are made.
For clients approaching retirement, plan design in 2027 and beyond remains an open question, and the survey found that 27% of current users who have concerns about taking a GLP-1 into retirement identify Medicare or insurance coverage as their single biggest worry.
The finding with the clearest practical implication is also one of the survey's starkest. Among current GLP-1 users who work with a financial professional, 59% expect that advisor to proactively discuss how GLP-1 costs and benefits affect their financial plan. Yet 47% of current users have never had that conversation. Among those who have discussed it, only 35% have done so.
The survey's breakdown of specific financial behaviors, such as debt, retirement account withdrawals, and reduced contributions, gives concrete shape to the employer coverage questions that benefits advisors navigating the GLP-1 debate in employer-sponsored health plans are already fielding.
The gap between client expectations and actual advisory conversations points to a specific opening. Clients who are taking on debt, drawing down savings, or quietly reducing their long-term care and retirement saving priorities because of either medication costs or health optimism are unlikely to raise those tradeoffs unprompted. The survey data suggest many of them are waiting for someone else to ask.
